



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/851,595	05/08/2001	Wei Gu	MNI-080CP	2613

7590 08/19/2003

INTELLECTUAL PROPERTY GROUP  
MILLENNIUM PHARMACEUTICALS, INC.  
75 SIDNEY STREET  
CAMBRIDGE, MA 02139

[REDACTED] EXAMINER

MERTZ, PREMA MARIA

ART UNIT	PAPER NUMBER
1646	16

DATE MAILED: 08/19/2003

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO
EXAMINER			
ART. INV.		PAPER NUMBER	16
DATE MAILED			

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

THE PERIOD FOR RESPONSE:

a)  is extended to run \_\_\_\_\_ or continues to run 3 months from the date of the final rejection  
b)  expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

Appellant's Brief is due in accordance with 37 CFR 1.192(a).  
 Applicant's response to the final rejection, filed \_\_\_\_\_ has been considered with the following effect, but it is not deemed to place the application in condition for allowance:  
1.  The proposed amendments to the claim and/or specification will not be entered and the final rejection stands because:  
a.  There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.  
b.  They raise new issues that would require further consideration and/or search. (See Note).  
c.  They raise the issue of new matter. (See Note).  
d.  They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.  
e.  They present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: The amendment to claim 23 violates the 35 USC 112, first para, and written description and cause rejection but the 35 USC 101 rejection over claims 23 is still valid.

2.  Newly proposed or amended claims \_\_\_\_\_ would be allowed if submitted in a separately filed amendment cancelling the non-allowable claims.  
3.  Upon the filing of an appeal, the proposed amendment  will be entered  will not be entered and the status of the claims will be as follows:

Claims allowed: \_\_\_\_\_

Claims objected to: \_\_\_\_\_

Claims rejected: 23 - 32

However;

Applicant's response has overcome the following rejection(s): \_\_\_\_\_

4.  The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because the contention that the presently claimed compositions are useful in the identification of compounds which modulate LGR6 in an attempt to identify compounds for treatment of LGR6 related disorders is an argument which cannot be accepted because there is no tangible, material presented.  
5.  The affidavit or exhibit will not be considered because applicant has not shown good and sufficient reasons why it was not earlier presented.

The proposed drawing correction  has  has not been approved by the examiner.

Other evidence of record which supports such a conclusion. Because a specific and substantial role for the LGR6 protein has not been demonstrated, an artisan would have no means of predicting what clinical effect the administration of the compounds would have on a subject.  
PTO-803 (REV. 5-89)